YAP1 and skin papilloma: Similar results were obtained by treatment of mice with the topical Src inhibitor (Dasatinib), which was able to drastically reduce YAP levels and nuclear localisation in untreated or TPA-treated skin, as well as in skin papillomas induced by a TPA+DMBA treatment regimen (Fig. 5D-I).